[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2024001617A - Composiciones biofarmaceuticas. - Google Patents

Composiciones biofarmaceuticas.

Info

Publication number
MX2024001617A
MX2024001617A MX2024001617A MX2024001617A MX2024001617A MX 2024001617 A MX2024001617 A MX 2024001617A MX 2024001617 A MX2024001617 A MX 2024001617A MX 2024001617 A MX2024001617 A MX 2024001617A MX 2024001617 A MX2024001617 A MX 2024001617A
Authority
MX
Mexico
Prior art keywords
compositions
biopharmaceutical compositions
biopharmaceutical
present disclosure
disclosure relates
Prior art date
Application number
MX2024001617A
Other languages
English (en)
Inventor
Myrna A Monck
Narendra B Bam
Jennifer Dally
Michelle Spatara
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2024001617(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2024001617A publication Critical patent/MX2024001617A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a composiciones, para tratar enfermedades mediadas por interleuquina 5 (IL-5), y métodos relacionados.
MX2024001617A 2015-08-24 2018-02-23 Composiciones biofarmaceuticas. MX2024001617A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
MX2024001617A true MX2024001617A (es) 2024-03-06

Family

ID=56877084

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002319A MX2018002319A (es) 2015-08-24 2016-08-22 Composiciones biofarmaceuticas.
MX2024001617A MX2024001617A (es) 2015-08-24 2018-02-23 Composiciones biofarmaceuticas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018002319A MX2018002319A (es) 2015-08-24 2016-08-22 Composiciones biofarmaceuticas.

Country Status (22)

Country Link
US (10) US10870695B2 (es)
EP (2) EP4056590A1 (es)
JP (4) JP6821659B2 (es)
KR (2) KR20240099511A (es)
CN (5) CN108137683A (es)
AU (1) AU2016311385C1 (es)
BR (1) BR112018003741A2 (es)
CA (1) CA2996088A1 (es)
CL (1) CL2018000499A1 (es)
CO (1) CO2018001840A2 (es)
CR (1) CR20180115A (es)
DO (1) DOP2018000057A (es)
EA (1) EA037487B1 (es)
IL (1) IL257539A (es)
MA (1) MA42692A (es)
MX (2) MX2018002319A (es)
PE (1) PE20181176A1 (es)
PH (1) PH12018500379A1 (es)
TW (2) TWI780988B (es)
UY (1) UY36868A (es)
WO (1) WO2017033121A1 (es)
ZA (1) ZA201801158B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4056590A1 (en) 2015-08-24 2022-09-14 GlaxoSmithKline Intellectual Property (No.2) Limited Biopharmaceutical compositions
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
PE20191662A1 (es) 2016-12-23 2019-11-11 Cephalon Inc Anticuerpos anti-il-5
UY37747A (es) 2017-05-26 2019-01-02 Glaxosmithkline Ip Dev Ltd Composiciones para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados
BR112019025736A2 (pt) * 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
TWI801425B (zh) 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
WO2019224724A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
WO2020200099A1 (zh) 2019-03-29 2020-10-08 江苏恒瑞医药股份有限公司 包含抗il-5抗体的药物组合物及其用途
IL293753A (en) * 2019-12-18 2022-08-01 Tesaro Inc Biopharmaceutical preparations and related methods
CN118251407A (zh) * 2021-09-22 2024-06-25 索诺玛生物治疗公司 Il5ra细胞表面标记物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016184A1 (en) 1992-02-06 1993-08-19 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
DK0800536T3 (da) 1994-12-23 2007-04-02 Smithkline Beecham Corp Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
WO2007100902A2 (en) 2006-02-28 2007-09-07 Oligasis Corporation Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
EP2152310A4 (en) 2007-04-30 2010-05-26 Glaxosmithkline Llc METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
KR20120129904A (ko) 2010-01-14 2012-11-28 공립대학법인 나고야 시립대학 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 질환의 예방 또는 치료를 위한 의약
MX2013009280A (es) 2011-02-09 2013-09-06 Glaxosmithkline Llc Formulaciones liofilizadas.
CA2832556A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
BR112013025845A2 (pt) 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
US20160235667A1 (en) 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
NZ722377A (en) 2014-01-24 2022-09-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
RU2724530C2 (ru) 2014-02-06 2020-06-23 Экс4 Фамасьютиклз (Остриэ) ГмбХ Выделенное антитело (варианты), способ получения антитела, выделенная нуклеиновая кислота, экспрессионная кассета (варианты), плазмида (варианты), клетка-хозяин, фармацевтический препарат, набор, способ лечения больного, подверженного риску или страдающего от инфекции e.coli, и способ диагностики определения инфекций e.coli
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
EP4056590A1 (en) 2015-08-24 2022-09-14 GlaxoSmithKline Intellectual Property (No.2) Limited Biopharmaceutical compositions

Also Published As

Publication number Publication date
JP2024123040A (ja) 2024-09-10
KR20240099511A (ko) 2024-06-28
JP2018526369A (ja) 2018-09-13
EP4056590A1 (en) 2022-09-14
WO2017033121A1 (en) 2017-03-02
TWI750133B (zh) 2021-12-21
TWI780988B (zh) 2022-10-11
US20210340247A1 (en) 2021-11-04
US20210340246A1 (en) 2021-11-04
CN116327921A (zh) 2023-06-27
CR20180115A (es) 2018-04-12
MA42692A (fr) 2018-07-04
CL2018000499A1 (es) 2018-07-06
CA2996088A1 (en) 2017-03-02
JP7463070B2 (ja) 2024-04-08
US11286298B2 (en) 2022-03-29
TW202233238A (zh) 2022-09-01
ZA201801158B (en) 2019-08-28
EA201890572A1 (ru) 2018-10-31
TW201722473A (zh) 2017-07-01
IL257539A (en) 2018-04-30
JP2022023049A (ja) 2022-02-07
US20240294629A1 (en) 2024-09-05
AU2016311385A1 (en) 2018-03-15
AU2016311385C1 (en) 2019-08-22
US20200199219A1 (en) 2020-06-25
US20220185878A1 (en) 2022-06-16
US20220380452A1 (en) 2022-12-01
US10870695B2 (en) 2020-12-22
KR20180037275A (ko) 2018-04-11
US20180251539A1 (en) 2018-09-06
JP6821659B2 (ja) 2021-01-27
CN116327923A (zh) 2023-06-27
US11459384B2 (en) 2022-10-04
PE20181176A1 (es) 2018-07-20
US20210332125A1 (en) 2021-10-28
JP2020033351A (ja) 2020-03-05
MX2018002319A (es) 2018-04-11
CO2018001840A2 (es) 2018-05-31
CN116474091A (zh) 2023-07-25
PH12018500379A1 (en) 2018-09-03
US11274148B2 (en) 2022-03-15
DOP2018000057A (es) 2018-03-15
EA037487B1 (ru) 2021-04-02
US20240294628A1 (en) 2024-09-05
CN116327922A (zh) 2023-06-27
US11299541B2 (en) 2022-04-12
AU2016311385B2 (en) 2019-05-09
US20240294630A1 (en) 2024-09-05
EP3341409A1 (en) 2018-07-04
BR112018003741A2 (pt) 2018-09-25
CN108137683A (zh) 2018-06-08
UY36868A (es) 2017-03-31

Similar Documents

Publication Publication Date Title
MX2024001617A (es) Composiciones biofarmaceuticas.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12018501159A1 (en) Composition and methods for immunooncology
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2019007020A (es) Anticuerpos il-11.
PH12016501763A1 (en) Multispecific antibodies
MX2024001394A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2018005829A (es) Composiciones para tratar el cabello.
EP3750907A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
MY191581A (en) Anti-pd-1 antibodies
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
SG10201909805XA (en) Surface modified polymer compositions
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MX2017008414A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
GB2568181A (en) Wheat
MX2015008310A (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.